Press Releases

WATERTOWN, Mass. , July 11, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ™ (fluocinolone

WATERTOWN, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr.

Expected closing of $25.5 million in capital to be used to accelerate EyePoint’s transformation into a commercial-stage specialty biopharmaceutical company Financing supports two near-term product launches anticipated in the first half of 2019 WATERTOWN, Mass.

WATERTOWN, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of Leonard M.

Completed Substantive Strategic Initiatives to Accelerate Transformation to a Commercial Company Conference Call and Webcast Today, May 8th , at 4:30 p.m. ET WATERTOWN, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed

WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018.

WATERTOWN, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ™ (fluocinolone

WATERTOWN, Mass. , April 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the U.S.

Acquisition and additional funding significantly accelerate the company's transformation to a specialty biopharmaceutical company with the potential to commercialize two ophthalmic products in 1H 2019 Icon Bioscience's DEXYCU ™ (dexamethasone intraocular suspension) 9% was approved by the FDA on

WATERTOWN, Mass. , March 19, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that its New Drug Application (NDA) for Durasert three-year treatment for posterior segment uveitis has been

WATERTOWN, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the Company

WATERTOWN, Mass. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the Company

Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months       Awaiting FDA Decision to Accept NDA Submission for Review Conference Call and Webcast Today, February 7th , at 4:30 p.m.

Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) --  pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development

Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th

Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases

WATERTOWN, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, today announced that the U.S. Food and Drug Administration (FDA) granted its request for a small business waiver of the Prescription

WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, announced today that Nancy Lurker , President and Chief Executive Officer, will present at the Annual Biotech Showcase conference on

Sustained Release Technology Well Tolerated and Provides Pain Reduction

NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7th , at 8:30 a.m. ET WATERTOWN, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.